Corporate Governance

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that improve the lives of people with neurological disorders.

Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS), as demonstrated by an increase in walking speed. The Company has one of the leading pipelines in the industry of novel neurological therapies. Acorda is currently developing a number of clinical and preclinical stage therapies. This pipeline addresses a range of disorders including post-stroke walking deficits, Parkinson’s disease, epilepsy, neuropathic pain, heart failure, MS and spinal cord injury.

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.

Chairperson Member Financial Expert
  Audit Committee Compensation Committee Compliance Committee Nomination
& Governance Committee
Scientific Committee
Barry Greene
Peder Jensen
John Kelley
Sandra Panem, Ph.D.
Lorin J. Randall
Steven M. Rauscher
Ian F. Smith
 Chairperson
 Member
 Financial Expert
AUDIT COMMITTEE
Lorin J. Randall
Steven M. Rauscher
Ian F. Smith
COMPENSATION COMMITTEE
Barry Greene
John Kelley
Sandra Panem, Ph.D.
COMPLIANCE COMMITTEE
Peder Jensen
Lorin J. Randall
Steven M. Rauscher
NOMINATIONS & GOVERNANCE COMMITTEE
Sandra Panem, Ph.D.
Lorin J. Randall
Ian F. Smith
SCIENTIFIC COMMITTEE
Peder Jensen
Sandra Panem, Ph.D.
Steven M. Rauscher

Stock Quote

ACOR (Common Stock) $ 31.69 -0.27 (-0.84%) Volume: 1,105,919 MORE August 27, 2015

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *